ALLK logo

Allakos Inc.


ALLK: Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.


Show ALLK Financials

Consumer Interest
SEC Filings

Recent trades of ALLK by members of U.S. Congress

Recently reported changes by institutional investors

Quarterly net insider trading by ALLK's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis Dec. 21, 2021
  • Patent Title: Methods and compositions for treating fibrotic diseases Sep. 15, 2020
  • Patent Title: Methods and compositions for treating siglec-8 associated diseases Jan. 22, 2019
  • Patent Title: Anti-siglec-8 antibodies and methods of use thereof Jan. 17, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of ALLK in WallStreetBets Daily Discussion


Recent insights relating to ALLK

CNBC Recommendations

Recent picks made for ALLK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ALLK

Corporate Flights

Flights by private jets registered to ALLK